Published in Law and Health Weekly, April 2nd, 2005
Cyberkinetics received regulatory clearance from the U.S. Food and Drug Administration (FDA) in March of 2004 to study the BrainGate Neural Interface System under an investigational device exemption (IDE). The first patient was enrolled through the Sargent Rehabilitation Center in Rhode Island and has successfully been able to use his thoughts and the BrainGate System to demonstrate that the system can be used to operate a computer, environmental...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly